Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: A randomized controlled trial in China

The burden of influenza is well known in the elderly and at-risk patients, but also in children. Especially in those under 5 years old, influenza may cause severe morbidity and mortality. Influenza infections and complications can be reduced by vaccination. In a randomized, endpoint-blinded, parallel group trial the immunogenicity and safety was studied of two trivalent inactivated surface antigen (subunit) influenza vaccines Influvac® and Agrippal® in healthy children as well as in adults and the elderly.